| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | IL-20; IL10D; ZCYTO10 |
| Entrez GeneID | 50604; |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human interleukin 20 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于IL-2抗体的代表性文献及其摘要：
1. **文献名称**：*Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes*
**作者**：Sockolosky JT, et al.
**摘要**：该研究设计了一种正交IL-2(orthoIL-2)系统，通过改造IL-2及其受体，使其仅与工程化T细胞结合，而避免激活天然免疫细胞。配套开发的IL-2抗体可特异性阻断内源性IL-2信号，从而增强工程化T细胞疗法的安全性和有效性(发表于*Science* 2018)。
2. **文献名称**：*Interleukin-2 receptor signaling: at the interface between tolerance and immunity*
**作者**：Malek TR, Castro I.
**摘要**：文章系统综述了IL-2及其受体(IL-2R)在免疫耐受和激活中的双重作用，重点讨论了靶向IL-2R的抗体(如抗CD25抗体)如何通过调控调节性T细胞(Treg)和效应T细胞的平衡，应用于自身免疫病和器官移植(发表于*Immunity* 2010)。
3. **文献名称**：*Anti-IL-2 monoclonal antibody enhances tumor-reactive CD8+ T cell responses by blocking IL-2 consumption in the tumor microenvironment*
**作者**：Boyman O, et al.
**摘要**：研究发现肿瘤微环境中的Treg细胞通过高表达IL-2Rα(CD25)消耗IL-2.导致效应T细胞活性被抑制。使用抗IL-2抗体阻断IL-2与Treg的结合后，可增加效应T细胞的IL-2利用，显著提升抗肿瘤免疫效果(发表于*Nature Medicine* 2014)。
---
**注**：以上文献可在PubMed或期刊官网检索原文，实际引用时需核对卷号及页码。
Interleukin-2 (IL-2) is a cytokine produced primarily by activated T cells, playing pivotal roles in immune regulation. It promotes the proliferation and differentiation of effector T cells, supports natural killer (NK) cell activity, and maintains regulatory T cells (Tregs) critical for immune tolerance. IL-2 exerts its effects by binding to a receptor complex comprising IL-2Rα (CD25), IL-2Rβ (CD122), and γc (CD132).
IL-2 antibodies are tools or therapeutics targeting either IL-2 itself or its receptor components. As research reagents, they block IL-2 signaling to study immune pathways or detect IL-2 levels in assays like ELISA. Therapeutically, anti-IL-2/IL-2R antibodies aim to modulate immune responses. For instance, anti-CD25 antibodies (e.g., basiliximab) are used in organ transplantation to prevent rejection by inhibiting T cell activation. Conversely, IL-2-antibody fusion proteins (e.g., "IL-2 immunocytokines") are explored in cancer immunotherapy to bias signaling toward effector T cells.
Challenges arise from IL-2's dual role in immunity: excessive blockade may impair infection defense or amplify autoimmunity, while uncontrolled stimulation risks inflammatory toxicity. Advances include engineered antibodies with selective receptor targeting to optimize therapeutic windows. Ongoing research focuses on refining specificity and delivery to balance immune activation and suppression, expanding IL-2 antibodies' potential in autoimmune diseases, cancer, and beyond.
×
